Burning Rock Dx(BNR) - 2024 Q3 - Quarterly Report

Burning Rock Reports Third Quarter 2024 Financial Results Recent Business Updates • Presented study results at the 2024 World Conference on Lung Cancer in September 2024. "Neoadjuvant sintilimab plus chemotherapy could be an optional treatment modality in selected EGFR-mutant NSCLC" and "Distinct Genomic and Immune Microenvironment Features of Solid or Micropapillary Predominant Subtype in Stage I Lung Adenocarcinomas". • Signed a strategic cooperation agreement with MGI Tech Co., Ltd in October 2024, aimin ...